The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

The effect of supplementing unscreened adults with vitamin D3 on mortality is unclear.

The D-Health Trial is funded by National Health and Medical Research Council.

Who Took Part

PubMed indexes the participants as adults and older adults.

Participants, staff, and investigators were blinded to study group allocation.

The primary endpoint was all-cause mortality assessed in all participants who were randomly assigned.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

The researchers also analysed mortality from cancer, cardiovascular disease, and other causes.

What Was Measured

The subject headings attached to it are Australia, Cardiovascular Diseases, Cholecalciferol, Dietary Supplements, Vitamin D and Vitamins.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 11 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (The lancet. Diabetes & endocrinology), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.